Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMH073T)

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Clinical Trial Drug(s)

Patented Agent(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Jun N terminal kinase (JNK)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
AM-111	DM4E9PK	Neurological disorder	6B60	Phase 3	[2]
BGP-15	DMYDM68	Type-2 diabetes	5A11	Phase 2	[3]
CC-401	DMPMO6G	Solid tumour/cancer	2A00-2F9Z	Phase 2	[4]
CC-930	DMHVEGJ	Discoid lupus erythematosus	EB51.0	Phase 2	[5]
PMID25991433-Compound-Q1	DMEMSB2	N. A.	N. A.	Patented	[1]
2,6-Dihydroanthra/1,9-Cd/Pyrazol-6-One	DMDN12L	Discovery agent	N.A.	Investigative	[6]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

References

1	c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
2	The JNK inhibitor XG-102 protects against TNBS-induced colitis.PLoS One.2012;7(3):e30985.
3	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4	Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49.
5	In vitro metabolism of a novel JNK inhibitor tanzisertib: interspecies differences in oxido-reduction and characterization of enzymes involved in metabolism. Xenobiotica. 2015;45(6):465-80.
6	c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis. J Clin Invest. 2001 Jul;108(1):73-81.